↓ Skip to main content

Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors

Overview of attention for article published in Investigational New Drugs, December 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#26 of 688)
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

twitter
7 tweeters
patent
2 patents
googleplus
2 Google+ users
video
1 video uploader

Citations

dimensions_citation
77 Dimensions

Readers on

mendeley
73 Mendeley
Title
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors
Published in
Investigational New Drugs, December 2013
DOI 10.1007/s10637-013-0047-4
Pubmed ID
Authors

E. M. Dunbar, B. S. Coats, A. L. Shroads, T. Langaee, A. Lew, J. R. Forder, J. J. Shuster, D. A. Wagner, P. W. Stacpoole

Abstract

Recurrent malignant brain tumors (RMBTs) carry a poor prognosis. Dichloroacetate (DCA) activates mitochondrial oxidative metabolism and has shown activity against several human cancers.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 1%
United States 1 1%
Unknown 71 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 22%
Student > Ph. D. Student 16 22%
Student > Bachelor 12 16%
Student > Master 7 10%
Student > Doctoral Student 6 8%
Other 16 22%
Readers by discipline Count As %
Medicine and Dentistry 26 36%
Agricultural and Biological Sciences 17 23%
Biochemistry, Genetics and Molecular Biology 9 12%
Unspecified 5 7%
Chemistry 5 7%
Other 11 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2019.
All research outputs
#1,275,204
of 13,218,736 outputs
Outputs from Investigational New Drugs
#26
of 688 outputs
Outputs of similar age
#26,545
of 214,830 outputs
Outputs of similar age from Investigational New Drugs
#1
of 21 outputs
Altmetric has tracked 13,218,736 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 688 research outputs from this source. They receive a mean Attention Score of 4.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 214,830 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.